Ironing Out the Details: New Anemia Treatments for Patients with Chronic Kidney Disease

Justin Horowitz, Pharm.D\(^1\), Roberto Collazo-Maldonado, M.D.\(^2\)

\(^1\)Department of Pharmacy Services, Methodist Dallas Medical Center, Dallas, Texas
\(^2\)Nephrology Division, Methodist Dallas Medical Center, Dallas, Texas

Introduction

There are 25 million people afflicted with kidney disease in United States. Anemia is a common complication of declining kidney function, and the severity of anemia highly correlates with the deterioration of glomerular filtration rate.\(^1\) Prior to the advent and approval of erythropoietin stimulating agents (ESAs) in 1989, blood transfusions were the only option available for the treatment of anemia, but came at the cost of volume and iron overload, transfusion related reactions, and exposure to HLA antigens from numerous donors, which prevented some patients from becoming transplant candidates. Anemia is associated with decreased quality of life, impairment in cardiac function, and mortality.\(^2\) Treatment of anemia in patients with chronic kidney disease is associated with a reduction in packed red blood cell (pRBC) transfusions and improved quality of life; however, no studies have validated a true mortality benefit by correcting anemia in patients with chronic kidney disease (CKD). Currently, the Kidney Disease: Improving Global Outcomes (KDIGO) and Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines strongly encourage the use of ESAs instead of pRBCs for the treatment of anemia associated with CKD.\(^1,3\)

As healthcare costs continue to be a driving force for decision-making, practitioners must weigh many options in a variety of treatments. In the setting of anemia secondary to CKD, recombinant human ESAs have widely held the market since the first approval in 1989. In 2005 Medicare spent approximately $2 billion on epoetin alfa alone, which was used in approximately 95% of all dialysis patients. By 2007 the cost to Medicare nearly doubled to $3.9 billion. A year later, in 2008, epoetin alfa was Medicare’s largest single pharmaceutical expenditure, and remains in the top 50 today.\(^4,5\) Over this time period hundreds of trials have been published studying outcomes with these agents, identifying efficacy, treatment targets, adverse effects, and appropriateness of use. It has not been until recently that new treatment options have surfaced. These options include long-acting erythropoietin agents, erythropoietin receptor agonists, and the novel hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI). In this article, we will review current therapy recommendations, and discuss exciting alternatives on the horizon (Table 1). These new therapies are a very exciting topic in nephrology and have the potential to change the way anemia of CKD is treated in the near future.

Table 1. Overview of treatments for chronic kidney disease associated anemia

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism of Action</th>
<th>Route of Administration</th>
<th>General Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epoetin alfa (Epogen®/Procrit®)</td>
<td>Recombinant Erythropoetin</td>
<td>SubQ/IV</td>
<td>50-100 units/kg thrice weekly</td>
</tr>
<tr>
<td>Darbepoetin alfa (Aranesp®)</td>
<td>Recombinant Erythropoetin</td>
<td>SubQ/IV</td>
<td>0.45 mcg/kg weekly 0.75 mcg/kg every two weeks</td>
</tr>
<tr>
<td>Methoxy polyethylene glycol-epoetin beta (Mincera®)</td>
<td>Continuous Erythropoetin Receptor Activator</td>
<td>SubQ/IV</td>
<td>0.6 mcg/kg every two weeks</td>
</tr>
<tr>
<td>Peginesatide (Omontys®)</td>
<td>Erythropoetin Receptor Agonists</td>
<td>SubQ/IV</td>
<td>0.04-0.08 mg/kg monthly</td>
</tr>
<tr>
<td>FG-4592 (Roxadustat)</td>
<td>HIF-Prolyl Hydroxylase Inhibitors</td>
<td>Oral</td>
<td>1.0-2.5 mg/kg thrice weekly</td>
</tr>
<tr>
<td>AKB-6548 (Vadadustat)</td>
<td>HIF-Prolyl Hydroxylase Inhibitors</td>
<td>Oral</td>
<td>Variable dosing once daily</td>
</tr>
<tr>
<td>GSK1278863</td>
<td>HIF-Prolyl Hydroxylase Inhibitors</td>
<td>Oral</td>
<td>Variable dosing once daily</td>
</tr>
</tbody>
</table>
Erythropoiesis Stimulating Agents: Epogen®, Procit®, Aranesp®

ESAs have a primary mechanism of action by stimulating red blood cell progenitors. Typical doses of ESAs are supraphysiologic to the natural, endogenous production of erythropoietin. The class of ESAs has significant data supporting their efficacy in increasing hemoglobin (Hgb) and reducing the need for pRBC transfusions. To promote the production of red blood cells through this mechanism, patients must have appropriate iron availability. For this reason, many patients require oral or intravenous iron therapy prior to or concomitantly with ESA therapy as iron deficiency is the most common cause of ESA resistance. Inflammatory processes including uremia, aluminum toxicity, infection and occult malignancy may cause a prolonged exposure to supraphysiologic doses of erythropoietin that may lead to sensitization and a decline in responsiveness to therapy.

Treatment thresholds and endpoints of therapy are highly studied topics in treating anemic patients with CKD. KDIGO guidelines recommend the utilization of ESAs in patients with a Hgb <10 g/dL and not to exceed 11.5 g/dL. This finding comes from multiple, large, randomized controlled trials including NHT and CHOIR, which were terminated early. The CHOIR study compared patients receiving epoetin alfa to achieve a maintenance Hgb target of 13.5 g/dL as compared to 11.3 g/dL. Higher rates or mortality, myocardial infarction, stroke or hospitalization for congestive heart failure were identified in the arm treated to a higher Hgb target (18% vs. 14%; HR 1.34; p=0.03). The difference in the composite endpoint was highly attributable to a non-significant trend toward increased risk of death in the higher Hgb goal group (7.3% vs. 5.0%; p=0.07). Following these results, the FDA issued a statement and required a boxed warning for all ESAs warning prescribers of these serious risks, particularly associated with higher Hgb targets. A cardiovascular benefit was not evident and required nearly two times the average dose of epoetin alfa to maintain these goal levels. Numerous studies have further validated the increased risk of mortality, cardiovascular and cerebrovascular events, vascular access thrombosis, thromboembolic events, and hypertension with the treatment of all ESAs. Furthermore, these agents should be avoided in patients with active malignancy if possible as numerous studies allude to poorer outcomes, including disease progression or relapse, thromboembolic events, and higher rates of mortality.9

Recombinant Human Erythropoietin

The utilization of epoetin alfa does not naturally mimic the endogenous release of erythropoietin. Traditionally, epoetin alfa is administered thrice weekly, resulting in short, intermittent bursts of plasma erythropoietin, leading to fluctuations in Hgb. This phenomenon of Hgb cycling may have an adverse effect as it can cause dysregulation of homeostasis and suboptimal patient outcomes. In a prospective study assessing long-term effects of Hgb cycling was conducted, suggesting an increased risk of cerebrovascular and cardiovascular disease, infection, and hospitalization in patients with high-amplitude fluctuations in Hgb compared to patients who maintained a target-range Hgb level.10-12 This finding further suggests improved outcomes with the use of long-acting erythropoietin agents, such as glycosylated recombinant human erythropoietin, and continuous erythropoietin receptor activators (CERA). Safety and efficacy studies have been performed comparing epoetin alfa administered thrice weekly versus once weekly or even every other week. These studies showed extended interval dosing of epoetin alfa to be equally efficacious at achieving goal Hgb targets but require significantly higher doses.13 However, a metaregression analysis performed by Koulouridis et al. demonstrated higher ESA doses might be associated with all-cause mortality and cardiovascular complications independent of hemoglobin concentration.14 Current guidelines recommend the use of ESAs as a class stating, “There is no evidence that any given ESA brand is superior to another in terms of patient outcomes.” This statement does not provide preference for one ESA over another, however this recommendation was made prior to the utilization and approval of methoxy polyethylene glycol-epoetin beta, a CERA.1

Glycosylated Recombinant Human Erythropoietin

Graduate Medical Education Journal of Methodist Health System | Dallas, Texas | Spring 2016 | Vol 13 | No 2
Aranesp® (darbepoetin alfa) is a glycosylated human erythropoietin agent which has a similar mechanism as epoetin alfa with a longer half-life. It was approved by the FDA in 2001 for indications of anemia associated with CKD, as well as due to chemotherapy in patients with cancer. Darbepoetin alfa has a half-life up to approximately 140 hours in CKD patients, which allows for dosing as infrequently as weekly or twice weekly.\(^{15}\)

### Erythropoietin Receptor Agonists: Omontys®

An alternative to recombinant human-erythropoiesis stimulating agents, peginesatide, was created by identifying peptides that interact with the erythropoietin receptor. This research led to the production of a peptide analog that mimicked the actions of ESAs as an erythropoietin receptor agonist, without the risk of causing pure red cell aplasia (PRCA), a rare hematologic disorder associated with transfusion-dependent anemia. The peptide was then pegylated to increase the half-life of this therapeutic agent to permit once monthly dosing. Four paramount randomized, controlled trials were published in New England Journal of Medicine (PEARL-1 & 2, and EMERALD-1 & 2), which validated this agent as being non-inferior to darbepoetin alfa in patients with chronic kidney disease, no matter dependence of dialysis.\(^{16,17}\)

The FDA approved Affymax’s Omontys® (peginesatide) as a subcutaneous and intravenous injection in 2012 for the treatment of anemia in adult patients on dialysis.\(^{18}\) Common side effects associated with this treatment included diarrhea, vomiting, hypertension, and arthralgias. In 2013, pooled data from the PEARL-1 & 2 studies determined there was an increase in a composite safety endpoint which included all-cause mortality, stroke, myocardial infarction, congestive heart failure, unstable angina, and cardiac arrhythmia in patients receiving peginesatide as compared to darbepoetin alfa (HR 1.32; 95% CI 0.97 to 1.81).\(^{19}\) This finding was not seen in the EMERALD studies, which was conducted in dialysis dependent patients. The drug was approved under a Risk Evaluation and Mitigation Strategy (REMS) due to a risk of potentially fatal cardiovascular and/or thromboembolic adverse events, and increased risk of these events in non-dialysis patients.

Following its approval, an increased incidence of severe hypersensitivity reactions was noted in post-marketing analysis with an incidence of 0.2%. Three documented deaths were attributed to these anaphylactic reactions. No identifiable risk factors could be attributed to this reaction, and the drug was subsequently recalled and withdrawn from market.\(^{20}\)

### Continuous Erythropoietin Receptor Agonists: Mircera®

Methoxy polyethylene glycol-epoetin beta (MG-EPO), the only continuous erythropoietin receptor activator currently on the market, has a unique pharmacokinetic profile as compared to other ESAs. MG-EPO maintains a significantly long half-life of approximately one week, and a time to peak of approximately 72 hours which permits dosing up to once monthly. Mircera® was approved by the FDA in 2015, and currently holds a single indication for anemia associated with CKD.\(^{21}\) A systematic review performed by Alsalimy and Awaisu evaluated articles comparing MG-EPO to darbepoetin alfa for efficacy and tolerability in non-dialysis CKD patients. Four trials met criteria consisting of 1,155 patients. Patients treated with MG-EPO had a lower incidence of Hgb above the target concentration of 12-13 g/dL (25.8% vs. 47%; p<0.0001), and thus fewer dose adjustments. Furthermore, patients receiving darbepoetin alfa required more RBC transfusions but achieved a Hgb response quicker (29 days vs 43 days). Although this was a systematic review and did not determine heterogeneity of the included studies, it alludes to some potential benefits of using MG-EPO.\(^{22}\)

Based on high quality trials, epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta have been found to be equally efficacious in reducing pRBC requirements, and improving quality of life in patients with chronic kidney disease. Of note, the most significant difference in outcomes with MG-EPO is its side effect profile. MG-EPO is associated with higher rates of treatment emergent hypertension and hypertension exacerbation, as well as higher mortality in cancer patients compared to other ESAs.\(^{23,24}\)
HIF-Prolyl Hydroxylase Inhibitors

FG-4592, or roxadustat, is a new novel agent being studied for the treatment of chronic kidney disease-associated anemia. The mechanism of action is quite unique and functions on the hypoxia-induced factor (HIF) pathway (Figure 1). HIFs are transcription factors that enhance the upregulation of erythropoietin in the setting of low oxygen conditions. During hypoxia, HIF-α accumulates and dimerizes with HIF-1β, which then translocates into the cell and acts as a transcription factor for the EPO gene. HIF-1β is constitutively produced, and the dimerized product of HIF1α and HIF-2α with HIFβ can also encode proteins that increase iron absorption and mobilization, as well as promote neovascular development through vascular endothelial growth factor and angiopoietins. This neovascular activity has been associated with decreased cardiac damage from myocardial ischemia, which may have some added benefit in the setting of anemia in chronic kidney disease.25 However, under normoxic conditions degradation of HIF-α occurs by a prolyl hydroxylase, PHD2. The hydroxylated HIF-α is recognized by the von Hippel-Lindau protein, which mediates polyubiquitination and ultimately results in rapid proteosomal degradation. Agents such as roxadustat are 2-oxoglutarate analogues, which stabilize HIF-α by inhibiting HIF prolyl hydroxylase.

Figure 1. Hypoxia Inducible Factor Pathway

The mechanistic benefit of stabilizing HIF-α is bimodal in that it can correct anemia by increasing production of erythropoietin and improve iron utilization.26,27 A phase I trial administered a single dose of a HIF-PHI (FG-2216) to nephric and anephric hemodialysis patients, as well as healthy volunteers. Plasma concentrations of erythropoietin increased 30.8, 14.5, and 12.7 times above baseline, respectively. Increased endogenous plasma erythropoietin concentrations generally peaked within 10-12 hours after administration.28 Furthermore, this agent can be administered orally three times weekly, which can improve compliance in the outpatient setting.

Hepcidin is a key regulator of iron metabolism and availability produced primarily by the liver. This hormone increases with inflammation and limits iron availability. It is thought that this mechanism began evolutionarily to reduce free iron during times of infection and other inflammatory processes. Hepcidin inhibits iron transport by binding to the iron export channel, ferroportin, which is located on the basolateral surface of gut enterocytes and the plasma membranes of reticuloendothelial cells. Furthermore, hepcidin also inhibits mobilization of iron from macrophages, as well as hepatocytes as part of the hepatic portal system. In vivo studies have identified many direct and indirect mechanisms in which the HIF pathway leads to downregulation of hepcidin and upregulation of erythropoietin and ferroportin, which promotes the mobilization of iron to support erythrocyte production.29,30

The capacity of oral roxadustat to improve iron efficiency in the treatment of anemia was validated in a Phase II study of 53 patients with a Hgb <10 g/dL, ferritin 50-300 ng/mL, transferrin saturation of 10-30%, and no intravenous iron therapy within 4 weeks prior to randomization. Intervention arms included dialysis patients receiving roxadustat with or without oral or intravenous iron products. The findings showed a dose-dependent elevation of Hgb ≥2 g/dL by week 7, regardless of iron supplementation or dialysis modality. However, the greatest Hgb changes were seen in patients receiving exogenous iron supplementation. The mean change in Hgb from baseline was 3.1 g/dL, but the largest increase was seen with intravenous iron therapy. Secondary findings showed a decrease
in hepcidin levels by 4 weeks, with largest reductions seen in patients on hemodialysis who were not receiving iron supplementation (80% of patients saw at least a decrease of 50% or greater, compared to 41% in those receiving intravenous iron). By completion of the study with 12 weeks of therapy, hepcidin rebounded beyond baseline in patients receiving intravenous iron. This finding is likely attributed to the competing feedback loop for iron regulation secondary to higher circulating iron levels. There was a greater response in Hgb in the last four weeks of therapy in patients receiving iron products compared to those who did not receive iron supplementation. This suggests initial treatment with iron supplementation to achieve an elevation in Hgb is not necessary, but may be required to maintain Hgb improvement.31

Common adverse events associated with roxadustat therapy included diarrhea (9.1%), headache (6.8%), back pain (4.5%), fatigue (4.5%) and hyperkalemia (4.5%) in a Phase II, multicenter, randomized, placebo-controlled trial in non-dialysis subjects with CKD. In the Phase II study conducted in dialysis patients, elevation in blood pressure, transient elevation in liver function tests, and abnormal electrocardiograms were identified.31,32

Currently, eight roxadustat Phase III studies are registered with the U.S. National Institutes of Health, and enrolling participants (Table 2). These studies are comparing roxadustat to epoetin alfa, darbepoetin alfa, and placebo in patients with chronic kidney disease with or without the requirement of dialysis. Primary outcome measures include long-term efficacy of maintaining Hgb, as well as safety outcomes including time to all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke up to 104 weeks following initiation of therapy. Furthermore, secondary outcomes include supplemental iron requirements, improvement in quality of life, and lipid lowering capacity. Other HIF-PHI agents are also in the pipeline, including GS1278863 and AKB-6548 (vadadustat). These agents have completed Phase II trials, as well, with promising results. Vadadustat, too, is currently enrolling patients for Phase III trials in dialysis and non-dialysis dependent patients with CKD.

### Table 2. Current Phase III Trials for HIF-PHI agents

<table>
<thead>
<tr>
<th>Clinical Trial</th>
<th>Population</th>
<th>Interventions</th>
<th>Primary Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT021    47341</td>
<td>DD-CKD</td>
<td>ROX vs. EPO</td>
<td>Time to occurrence of MACE</td>
</tr>
<tr>
<td>NCT022    78314</td>
<td>DD-CKD</td>
<td>ROX vs. EPO vs. DPO</td>
<td>Hgb response with/without rescue therapy</td>
</tr>
<tr>
<td>NCT022    73726</td>
<td>DD-CKD</td>
<td>ROX vs. EPO</td>
<td>Hgb response with/without rescue therapy</td>
</tr>
<tr>
<td>NCT020    52310</td>
<td>DD-CKD</td>
<td>ROX vs. EPO</td>
<td>Hgb from baseline to average levels</td>
</tr>
<tr>
<td>NCT021    46627</td>
<td>ND-CKD</td>
<td>ROX vs. placebo</td>
<td>Time to occurrence of MACE</td>
</tr>
<tr>
<td>NCT018    87600</td>
<td>ND-CKD</td>
<td>ROX vs. placebo</td>
<td>Response to treatment &amp; maintenance of Hgb</td>
</tr>
<tr>
<td>NCT017    50190</td>
<td>ND-CKD</td>
<td>ROX vs. placebo</td>
<td>Response to treatment &amp; maintenance of Hgb</td>
</tr>
<tr>
<td>NCT020    21318</td>
<td>ND-CKD</td>
<td>ROX vs. DPO</td>
<td>Hgb response without rescue therapy</td>
</tr>
<tr>
<td>NCT026    48347</td>
<td>ND-CKD</td>
<td>VAD vs. DPO</td>
<td>Hgb change from baseline and MACE</td>
</tr>
<tr>
<td>NCT026    80574</td>
<td>ND-CKD</td>
<td>VAD vs. DPO</td>
<td>Hgb change from baseline and MACE</td>
</tr>
</tbody>
</table>

**Clinical Trials**

- **NCT021 47341**: DD-CKD - dialysis-dependent chronic kidney disease; ND-CKD - non-dialysis chronic kidney disease; ROX = roxadustat; EPO = epoetin alfa; DPO = darbepoetin alfa; VAD = vadadustat; MACE = major adverse cardiovascular events; Hgb = hemoglobin

**Population**

- **DD-CKD**: dialysis or dialysis dependent patients with CKD.
- **ND-CKD**: non-dialysis patients with CKD.

**Interventions**

- **ROX vs. EPO**: Comparison of roxadustat to epoetin alfa.
- **ROX vs. EPO vs. DPO**: Comparison of roxadustat to epoetin alfa and darbepoetin alfa.
- **ROX vs. placebo**: Comparison of roxadustat to placebo.
- **VAD vs. DPO**: Comparison of vadadustat to darbepoetin alfa.

**Primary Outcome**

- **Time to occurrence of MACE**: Time to occurrence of major adverse cardiovascular events.
- **Response to treatment & maintenance of Hgb**: Response to treatment and maintenance of Hgb levels.
- **Hgb response without rescue therapy**: Response to treatment without the need for rescue therapy.
- **Hgb change from baseline and MACE**: Change in Hgb levels from baseline and major adverse cardiovascular events.

**Conclusion**

Although current guidelines do not show preference for one ESA as compared to another, epoetin alfa has generally remained the mainstay of therapy for CKD associated anemia. Long-acting ESAs such as darbepoetin alfa and MG-EPO are attractive alternatives due to convenience of infrequent dosing, and theoretical potential for improved long-term outcomes. Unfortunately, however, this class of drugs requires repletion and maintenance with exogenous iron. Furthermore, ESAs show diminished efficacy over time.

Previous alternatives to ESAs, such as erythropoietin receptor agonists, showed significant promise. Peginesatide was found to be non-inferior to ESA therapy, but carried increased risk of poor cardiovascular outcomes in Phase III trials. It was not until post-marketing analysis revealed a high rate of hypersensitivity reactions that it was pulled from the market.

The novel HIF-PHI agents have shown promising results in current Phase II trials. The mechanism of action of these agents closely mimics physiologic regulation of erythropoietin production. Not only are these agents capable of increasing Hgb, but they reduce hepcidin, and thus promote mobilization of endogenous iron. These agents are the first to offer an oral option for the treatment of anemia in CKD. The results of the Phase III trials are highly awaited.
as these agents are exciting and refreshing alternatives to ESAs which have remained commonplace since their approval over two decades ago. Some of these trials are expected to be completed by 2017, in which FDA approval will hopefully soon follow. These new agents may revolutionize the treatment of anemia and have the potential to impact the wellbeing of the 25 million people affected with CKD in this country. These new drug classes have the world of nephrology on the edge of its seat waiting with anticipation.

References

18. FDA Press Release. FDA approves Omontys to treat anemia in adult patients on dialysis. 2012.


